Orthocare Innovations, LLC赞助的临床试验
总计246个结果
-
SCRI Development Innovations, LLCGlaxoSmithKline完全的
-
SCRI Development Innovations, LLCBayer完全的
-
SCRI Development Innovations, LLCNovartis撤销
-
SCRI Development Innovations, LLCBiogen完全的
-
SCRI Development Innovations, LLCGlaxoSmithKline完全的
-
SCRI Development Innovations, LLCNovartis完全的
-
SCRI Development Innovations, LLCNovartis完全的
-
SCRI Development Innovations, LLCPfizer完全的
-
SCRI Development Innovations, LLCNovartis撤销
-
SCRI Development Innovations, LLCAmgen完全的
-
SCRI Development Innovations, LLCBayer完全的
-
SCRI Development Innovations, LLCNovartis完全的
-
SCRI Development Innovations, LLCBayer完全的
-
SCRI Development Innovations, LLCNovartis完全的
-
SCRI Development Innovations, LLCAstraZeneca完全的
-
SCRI Development Innovations, LLCBiogen完全的
-
SCRI Development Innovations, LLCNovartis完全的
-
SCRI Development Innovations, LLCBayer完全的
-
SCRI Development Innovations, LLCPfizer完全的
-
SCRI Development Innovations, LLCJanssen Research & Development, LLC招聘中
-
SCRI Development Innovations, LLCSeagen Inc.招聘中
-
SCRI Development Innovations, LLCIncyte Corporation终止
-
SCRI Development Innovations, LLCNovartis Pharmaceuticals完全的Metastatic or Unresectable Solid Tumor Malignancy美国
-
SCRI Development Innovations, LLCGenentech, Inc.终止
-
SCRI Development Innovations, LLCGenentech, Inc.完全的
-
SCRI Development Innovations, LLCCelgene Corporation终止
-
SCRI Development Innovations, LLCSirtex Medical完全的
-
SCRI Development Innovations, LLCNovartis Pharmaceuticals终止